Biome Secures FaBA Co-investment for IP Development
● Biome signs co-investment agreement with Australia’s Food and Beverage Accelerator (FaBA) for a jointly funded IP development program ●… Read more
Biome Australia Ltd -Positive Results on Clinical Development of BMB18
● Biome has received positive results of core functional characterisation studies of its strain BMB18 ● The strain demonstrated an… Read more
Biome’s Australian Distribution Passes 6000 Health Retail and Practitioner Locations
● Biome increases its distribution in Australian practitioner and pharmacy markets to 6,000+ locations ● 20% growth in distribution footprint… Read more
BIO Quarterly Activities & Appendix 4C December 2024
● Biome records $234k EBITDA for Q2, up 92% vs Q11 ● Record cash receipts of $4.34m in Q2, up… Read more
Biome reports record quarterly sales revenue for Q2 FY25
Biome Australia Limited (ASX: BIO) has reported impressive financial results for the second quarter of fiscal year 2025 (Q2 FY25). Financial… Read more
Q2 FY25 Revenue Guidance
● Biome forecast Q2 FY25 sales revenue to surpass $4.5m
Biome Company Presentation
Over 5,000 distribution points (Aus) following successful launch with Priceline Pharmacy Average shopper ~2 units per transaction and 6 visits… Read more
Biome Strain Development Program Success
● Biome has successfully completed the identification, commercial validation and initial characterisation of the probiotic strain Lactobacillus plantarum BMB18 ●… Read more
Biome Australia Business and International Market Update
● Following a successful test market launch in Canada, Biome moves to an official market launch in both health retail… Read more